Patient communication for PRP treatments: education and expectation management

The explanation does not need to begin with cytokines, growth factors or centrifugation physics. A few basic relationships are more important at first.

PRP is prepared from the patient’s own blood. After blood collection, blood components are separated using a preparation process. This produces a plasma fraction containing platelets and signalling substances released, or capable of being released, by them.

These biological properties explain why PRP is studied for different regenerative applications. On their own, however, they do not prove a clinical treatment benefit.

For a more detailed explanation of the biological background, see the professional article Platelet-rich plasma: biological principles of PRP therapy.

“We prepare PRP from your own blood. The platelets it contains release various biologically active signalling substances. There are positive study data for some applications. However, those data cannot reliably predict how strongly you personally will respond to treatment.”

A more useful first question is: “What do you personally expect from the treatment?”

A patient with hair loss may define success as complete restoration of previous hair density. With knee osteoarthritis, the expectation may be permanent freedom from pain or even structural restoration of joint cartilage. With an aesthetic treatment, a patient may expect a clearly visible change after a single session.

These expectations should become visible before treatment starts. More useful than the general question “What would you like?” are specific follow-up questions:

• What change would you consider a good result?
• When do you expect that change?
• What would you consider a disappointing result?
• How do we want to assess together later whether something has actually changed?

This turns a vague hope into a treatment goal that can be evaluated.

Section 630e of the German Civil Code (BGB) requires patients to be informed about the circumstances material to their consent. These include, in particular, the nature, scope and performance of the measure, expected consequences and risks, and its necessity, suitability and prospects of success with regard to diagnosis or treatment. The information must be understandable, generally provided orally, and given early enough for the patient to make a considered decision.

A signed form therefore does not replace an informed-consent discussion.

Precise wording is also important when discussing alternatives. The law does not require every theoretically conceivable alternative to be listed. Other methods must be discussed in particular when several medically equally indicated and customary methods may result in substantially different burdens, risks or chances of recovery.

For medical treatment methods that are not yet generally accepted German Federal Court of Justice case law imposes higher requirements. The patient must then be clearly informed that the method is not, or not yet, medical standard and that previously unknown risks may exist.

PRP is legally more than “own blood”

Blood, plasma or serum preparations obtained from blood, and preparations made from blood components, are treated as blood preparations under the German Medicinal Products Act. Under certain conditions, special rules apply when physicians prepare them for personal use in a specific patient. Blood collection is also regulated by law.

The professional and manufacturing-law classification is explained in more detail in the article Who may perform PRP? which separates blood collection, preparation, application and responsibility.

For patient communication, the main point is: “Autologous” is not a sufficient description of safety, efficacy or regulatory classification.

One of the most important rules is: Do not speak about the efficacy of “PRP in general”. Results studied for one indication cannot automatically be transferred to another. Differences in preparation, cellular composition and treatment protocols also make blanket statements difficult.

The technical guide explains why protocols cannot simply be transferred from one system to another: Combining PRP tubes and centrifuges correctly.

For knee osteoarthritis, current meta-analyses show positive signals for pain and function, while the literature remains heterogeneous and includes conflicting findings. In particular, this does not support a claim that PRP rebuilds joint cartilage.

Androgenetic alopecia also has positive study signals, but certainty of the evidence is limited and preparation methods differ considerably. The individual effect should not be guaranteed. A more detailed assessment is available here: PRP for hair loss: what do current studies show?.

The same principle applies to aesthetic uses: individual studies and meta-analyses may report positive results without supporting a general statement that “PRP rejuvenates the skin”.

A blanket statement that a patient needs three, four or six sessions and will then see a specific result is too crude. The number and spacing of applications depend on the protocol and area of use.

It is more useful to define before treatment when follow-up should take place and which criteria will be used to decide whether to continue.

“Before we begin, we agree when we will assess progress. If no relevant effect is apparent at that indication- and protocol-dependent time point, we will review together whether continuing treatment is medically appropriate.”

Expectation management needs baseline values

“It looks better” is an unreliable follow-up criterion. Where possible for the indication, the method used to assess the outcome should be defined before treatment begins. Depending on the application, this may include clinical findings, suitable scores, standardised photographs or objective measurements.

What matters less is which instrument is chosen than that it is defined before treatment and used as consistently as possible at follow-up.

Preparing PRP from autologous blood reduces certain risks associated with foreign products. It does not mean that blood collection, processing and injection are free of adverse effects or complications.

Which risks are relevant depends on the application, body region, injection technique, comorbidities and other patient-specific factors. Typical transient reactions can include pain, swelling, redness or bruising. General risks of invasive procedures such as infection or bleeding also apply.

Wording such as “PRP is virtually free of side effects because it is your own blood” should therefore be avoided.

Present numbers so they can be understood

Where reliable frequency data are available, natural frequencies can be easier to understand than relative changes. The direction of wording can also affect perception. Positive framing must never be used to minimise risks.

If a specific frequency is well established, it may be useful to present both sides—for example, “3 out of 10 report X; 7 out of 10 do not”. This keeps the information complete and easier to interpret.

Teach-back instead of “Did you understand everything?”

With the teach-back method, the patient explains in their own words what they understood. This tests the clarity of the explanation rather than the patient’s knowledge.

“To make sure I explained it clearly: could you briefly tell me in your own words what goal we are pursuing with the treatment and what we cannot guarantee?”

For PRP, teach-back is particularly useful for checking whether the treatment goal, limits of the prospects of success, key risks and planned follow-up time have been understood.

For aesthetically motivated treatments, baseline expectations should be assessed particularly carefully. Body dysmorphic disorder is considerably more common in aesthetic patient populations than in the general population.

This does not mean that every patient with high expectations has a mental disorder. A screening questionnaire is not a diagnosis. However, conspicuous expectations can be a reason to look more closely.

Possible warning signs include an extreme focus on minimal or barely visible features, repeated dissatisfaction with previous aesthetic treatments, or the expectation that a physical change will solve broad social or personal problems.

If there is a well-founded concern, it may be appropriate to postpone an elective aesthetic procedure and recommend further professional assessment.

Before-and-after images can be useful for internal medical follow-up. Conditions should be as reproducible as possible: comparable distance, lighting, camera position and posture; for hair treatments, a consistent parting should also be used where possible.

Medical photographic documentation and promotional use are different purposes. Consent to medical photography should not automatically be treated as permission for use on a website, social media or other advertising.

Public before-and-after advertising is subject to substantial restrictions, particularly for aesthetic procedures. In 2025, the German Federal Court of Justice held in relation to hyaluronic-acid injections intended to alter appearance that instrument-assisted injections can fall under the relevant advertising prohibition in the German Heilmittelwerbegesetz. This judgment should not be applied automatically to all PRP applications; classification depends on the nature and purpose of the procedure.

If it is known, or there are sufficient indications, that full reimbursement by a third party is not assured, Section 630c(3) BGB requires the patient to receive written-form information about the expected costs before treatment begins.

The law requires text form; it does not necessarily require a signed cost estimate. For planned treatment series, it should also be clear whether further applications may become necessary and which criteria will be used to decide.

For a broader professional overview of procedure, effects, limitations and costs, see PRP treatment: effects, costs and procedure.

Is a fixed reflection period required between counselling and treatment?

German law does not specify a fixed number of hours or days for ordinary PRP treatments. The information must be provided early enough for the patient to make a considered decision.

For elective, non-urgent and particularly purely aesthetic procedures, a time interval between detailed counselling and treatment may be sensible. However, there is no general statutory three-appointment requirement.

The following self-check is deliberately not described as “12 statutory mandatory elements”. Depending on indication and procedure, individual points may have different relevance. As a practice standard, they help identify common gaps early.

1. Clarify indication and expectations. What is being treated? What specific result does the patient expect? Is that goal realistic?
2. Explain PRP clearly. Separate the biological mechanism from evidence of clinical efficacy.
3. Assess evidence by indication. Do not explain “PRP in general”; discuss the data for the specific application.
4. Discuss risks and, where applicable, alternatives. Neither downplay nor unnecessarily dramatise them.
5. Clarify costs and decision time. If reimbursement is not assured, provide the expected costs in text form before treatment begins.
6. Document the baseline. Where useful, use a score, measurement or standardised photograph.
7. Check understanding. Teach-back is more informative than asking “Did you understand everything?”.
8. Set the follow-up time. Define in advance when and by which criteria continuation or discontinuation will be decided.

The key message: “We can explain the goal of the PRP treatment, what current research shows for this application and what risks exist. We cannot guarantee how your body will respond individually.”

1. BGB Section 630e – duty to inform.
2. BGB Section 630c – cooperation of the parties; financial information.
3. BGB Section 630f – treatment documentation.
4. AMG Section 4 – definitions, particularly blood preparations; additionally AMG Section 13.
5. TFG Section 7 – requirements for blood collection.
6. German Federal Court of Justice, judgment of 18 May 2021 – VI ZR 401/19: informed consent for treatment methods not yet generally accepted.
7. German Federal Court of Justice, judgment of 31 July 2025 – I ZR 170/24: before-and-after advertising for instrument-assisted injections intended to alter appearance.
8. Bensa A. et al. PRP Injections for the Treatment of Knee Osteoarthritis. American Journal of Sports Medicine, 2025. PMID: 39751394.
9. Yao et al. PRP combined with minoxidil for androgenetic alopecia. PLoS One, 2024. PMID: 39197003.
10. Systematic/meta-analytic data on microneedling/PRP for acne scars, 2026. PMID: 42324392.
11. AHRQ – Teach-Back.
12. Veale D. et al. Body dysmorphic disorder in different settings: a systematic review. Body Image, 2016. PMID: 27498379.
13. Barnes K. et al. Can Positive Framing Reduce Nocebo Side Effects? Frontiers in Pharmacology, 2019;10:167.